Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds from financing expected to extend cash runway into late 2025 COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of health

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023. The USD $2.5 million capital commitment will be in the form of USD $1.0 million i

Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH), a leading provider of care in the home to pediatric, adults, and geriatric patients, announced that it has amended its securitization facility to extend its maturity to July 31, 2026. The amended agreement continues to provide for total availability of $175 million. Matt Buckhalter, Interim CFO of Aveanna, stated, “We are pleased to extend this credit facility with our banking partners. We believe that this facility provides ample liqu

Financing, available in multiple tranches over the next three years, could extend the Company’s runway into Q4 2024 Transaction will enable Evaxion to advance its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to USD 20 mill

Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease Self-funded medical research organisation and charity, LifeArc, to launch a groundbreaking Rare Disease Translational Challenge that will invest more than £100m by 2030 to improve the lives of people living with a rare disease. The Challenge will offer funding and support to researchers to help find new diagnostic technologies, develop new treatments, accelerate new research and remove some

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and offering expenses, were

Funding from second closing extends cash runway to mid-2025 to advance the company’s HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission initiated and on track for completion in mid-2023 with potential for U.S. approval in the first half of 2024 Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has completed the second closing of its previously announced securities purchase agreement, resulting in $3

Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women's Health, today announces that it obtained access to a new tranche of the amended loan facility concluded with funds managed by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC ("Whitebox", and together with Highbridge, each a "Lender") for an amount of EUR 12.5 million. On 8 August 2022, the Company and the Lenders entered into an initial t

–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in PD– –IND-enabling studies ongoing to support Phase 1 clinical trial initiation in 2024– Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced it has received a research grant from The M

Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and warrants Additional reduction-in-force by approximately 44% as it continues to explore strategic alternatives Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologi